Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name… Read more
Avadel Pharmaceuticals PLC (AVDL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.237x
Based on the latest financial reports, Avadel Pharmaceuticals PLC (AVDL) has a cash flow conversion efficiency ratio of 0.237x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($23.26 Million) by net assets ($98.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Avadel Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Avadel Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Avadel Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avadel Pharmaceuticals PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Siriuspoint Ltd
NYSE:SPNT
|
0.004x |
|
Gold Road Resources Limited
PINK:ELKMF
|
0.122x |
|
Indian Railway Finance Corporation Limited
NSE:IRFC
|
-0.247x |
|
Harley-Davidson Inc
NYSE:HOG
|
0.048x |
|
Sime Darby Bhd
KLSE:4197
|
0.065x |
|
SIGMASTAR TECH LTD
SHE:301536
|
0.014x |
|
Mobimo Holding AG
LSE:0QQY
|
0.002x |
|
Pou Chen Corp
TW:9904
|
0.011x |
Annual Cash Flow Conversion Efficiency for Avadel Pharmaceuticals PLC (1996–2024)
The table below shows the annual cash flow conversion efficiency of Avadel Pharmaceuticals PLC from 1996 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $73.85 Million | $-46.91 Million | -0.635x | +56.63% |
| 2023-12-31 | $87.74 Million | $-128.51 Million | -1.465x | -144.05% |
| 2022-12-31 | $-21.14 Million | $-70.30 Million | 3.325x | +436.50% |
| 2021-12-31 | $78.24 Million | $-77.31 Million | -0.988x | -228.99% |
| 2020-12-31 | $162.27 Million | $-48.73 Million | -0.300x | -122.88% |
| 2019-12-31 | $-29.20 Million | $-38.33 Million | 1.313x | +104.41% |
| 2018-12-31 | $2.78 Million | $-82.72 Million | -29.754x | -15200.73% |
| 2017-12-31 | $84.56 Million | $16.66 Million | 0.197x | -56.14% |
| 2016-12-31 | $42.07 Million | $18.90 Million | 0.449x | -63.83% |
| 2015-12-31 | $67.86 Million | $84.29 Million | 1.242x | +391.22% |
| 2014-12-31 | $24.89 Million | $-10.62 Million | -0.427x | -119.62% |
| 2013-12-31 | $-9.51 Million | $-20.68 Million | 2.174x | +386.55% |
| 2012-12-31 | $30.50 Million | $-23.14 Million | -0.759x | -118.93% |
| 2011-12-31 | $29.79 Million | $-10.32 Million | -0.346x | -130.51% |
| 2010-12-31 | $36.30 Million | $-5.46 Million | -0.150x | -182.29% |
| 2009-12-31 | $44.86 Million | $8.20 Million | 0.183x | +218.11% |
| 2008-12-31 | $48.55 Million | $-7.51 Million | -0.155x | +56.09% |
| 2007-12-31 | $54.63 Million | $-19.24 Million | -0.352x | +13.76% |
| 2006-12-31 | $73.03 Million | $-29.83 Million | -0.408x | -82.54% |
| 2005-12-31 | $86.65 Million | $-19.39 Million | -0.224x | -529.51% |
| 2004-12-31 | $116.76 Million | $-4.15 Million | -0.036x | -126.76% |
| 2003-12-31 | $92.06 Million | $12.23 Million | 0.133x | -81.40% |
| 2002-12-31 | $12.29 Million | $8.77 Million | 0.714x | +292.55% |
| 2001-12-31 | $7.51 Million | $-2.78 Million | -0.371x | +28.24% |
| 2000-12-31 | $10.88 Million | $-5.62 Million | -0.517x | -10.51% |
| 1999-12-31 | $9.07 Million | $-4.24 Million | -0.468x | -1.55% |
| 1998-12-31 | $17.79 Million | $-8.19 Million | -0.460x | +26.03% |
| 1997-12-31 | $14.30 Million | $-8.90 Million | -0.622x | -242.31% |
| 1996-12-31 | $23.10 Million | $-4.20 Million | -0.182x | -- |